Ampersand Health is a behavioural health company focused on immunology and inflammation, helping people with complex long term conditions navigate the journey from diagnosis to sustained remission.
Co-founded by senior clinicians and built with patients at King’s College Hospital and The Royal London, Ampersand’s platform integrates behaviour change programmes, health analytics and real-time disease monitoring, allowing for more proactive, personalised care. With 1.5 billion fully consented data points, the company is pioneering the development of predictive digital biomarkers, with early models demonstrating 80% efficacy in identifying disease flares early.
The company partners with leading hospitals, pharma companies, research institutions, and patient groups in the US and the UK, including IQVIA, UPenn, AbbVie and Versus Arthritis to ensure that the patient journey is better understood and fully supported. It is launching in France and Germany in 2025.
Ampersand’s impact is evidenced in 15 publications from real world and clinical studies. The platform has been shown to support reductions in A&E visits of 50-89%, cuts in unnecessary appointments by 47%, and a 650% financial ROI for hospitals. Independent research from Mt Sinai, University of Michigan, University of Leiden and elsewhere consistently ranks Ampersand’s behavioural interventions as industry leading.
A recipient of awards from Innovate UK, NHSX and others, Ampersand is backed by notable impact investors including Simplyhealth Ventures, the Kent Life Sciences Fund and Crista Galli Ventures.